A randomized, open‐label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV‐1‐infected patients with lipodystrophy

Background Several studies have shown beneficial effects of recombinant human growth hormone (r‐hGH) in reducing visceral adipose tissue (VAT) in HIV‐1‐infected patients with lipodystrophy. Methods Patients were randomized to r‐hGH 4 mg daily (group A) or three times per week (group B) over 12 weeks...

Full description

Saved in:
Bibliographic Details
Published in:HIV medicine 2006-09, Vol.7 (6), p.397-403
Main Authors: Bickel, M, Zangos, S, Jacobi, V, Lutz, T, Knecht, G, Goebel, F, Staszewski, S, Klauke, S
Format: Article
Language:English
Subjects:
Adipose Tissue - anatomy & histology
Adipose Tissue - drug effects
Body Composition - drug effects
Fasting - metabolism
Female
growth hormone
HIV Infections - complications
HIV-1
HIV-Associated Lipodystrophy Syndrome - drug therapy
Human Growth Hormone - administration & dosage
Human Growth Hormone - therapeutic use
Human immunodeficiency virus
Humans
lipodystrophy
Magnetic Resonance Imaging
Male
Middle Aged
Recombinant Proteins - administration & dosage
Recombinant Proteins - therapeutic use
Treatment Outcome
visceral adipose tissue
visceral adiposity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Several studies have shown beneficial effects of recombinant human growth hormone (r‐hGH) in reducing visceral adipose tissue (VAT) in HIV‐1‐infected patients with lipodystrophy. Methods Patients were randomized to r‐hGH 4 mg daily (group A) or three times per week (group B) over 12 weeks, followed by a 2 mg daily maintenance dose for 12 weeks. Magnetic resonance imaging (MRI) scans were performed to assess body composition. Results A total of 26 subjects were included in the study. VAT was reduced overall by 35.1 cm2 (29.5%) at week 12 and by 49 cm2 (39.9%) at week 24, respectively, compared with baseline (P
ISSN:1464-2662
1468-1293
DOI:10.1111/j.1468-1293.2006.00399.x